Challenges to the Design, Execution, and Analysis of Randomized Controlled Trials for Inflammatory Bowel Disease-Reference-Cited by-同舟云学术

Challenges to the Design, Execution, and Analysis of Randomized Controlled Trials for Inflammatory Bowel Disease

Published:2012-12 Issue:6 Volume:143 Page:1461-1469
ISSN:0016-5085
Container-title:Gastroenterology
language:en
Short-container-title:Gastroenterology

Author:

D'Haens Geert,Feagan Brian,Colombel Jean–Frédéric,Sandborn William J.,Reinisch Walter,Rutgeerts Paul,Carbonnel Frank,Mary Jean–Yves,Danese Silvio,Fedorak Richard N.,Hanauer Steven,Lémann Marc

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference56 articles.

1. Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease;D'Haens;Inflamm Bowel Dis,2009

2. Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials;Sandborn;Am J Gastroenterol,2005

3. European evidence-based Consensus on the management of ulcerative colitis: current management;Travis;J Crohns Colitis,2008

4. Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis;Ford;Am J Gastroenterol,2011

5. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease;Sandborn;Gastroenterology,2002

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Headache in patients with inflammatory bowel disease: Migraine prevalence according to the Migraine Screening-Questionnaire (MS-Q) and headache characteristics;Gastroenterología y Hepatología;2024-01

2. Headache in patients with inflammatory bowel disease: Migraine prevalence according to the Migraine Screening-Questionnaire (MS-Q) and headache characteristics;Gastroenterología y Hepatología (English Edition);2024-01

3. PF-431396 hydrate inhibition of kinase phosphorylation during adherent-invasive Escherichia coli infection inhibits intra-macrophage replication and inflammatory cytokine release;Microbiology;2023-06-13

4. Real‐world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA‐SWITCH study;Alimentary Pharmacology & Therapeutics;2023-04-23

5. Withdrawal of Anti-Tumour Necrosis Factor in Inflammatory Bowel Disease Patients in Remission: A Randomised Placebo-Controlled Clinical Trial of GETECCU;2023